Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Erratum to: Evaluation of the Safety, Tolerability, and Pharmacokinetics of Gammaplex® 10% Versus Gammaplex® 5% in Subjects with Primary Immunodeficiency

Erratum to: Evaluation of the Safety, Tolerability, and Pharmacokinetics of Gammaplex® 10% Versus... J Clin Immunol (2017) 37:613 DOI 10.1007/s10875-017-0418-2 ERRATUM Erratum to: Evaluation of the Safety, Tolerability, and Pharmacokinetics of Gammaplex® 10% Versus Gammaplex® 5% in Subjects with Primary Immunodeficiency 1 2 3 4 Richard L. Wasserman & Isaac R. Melamed & Mark R. Stein & Stephen Jolles & 5 6 Miranda Norton & James N. Moy & for the GMX07 Study Group Published online: 17 July 2017 The Author(s) 2017. This article is an open access publication Erratum to: J Clin Immunol (2017) 37:301–310. page 301–310 the author decided to opt for Open Choice and DOI 10.1007/s10875-017-0383-9 to make the article an open access publication. Therefore, the copyright of the article has been changed to © The Author(s) The article Evaluation of the Safety, Tolerability, and 2017 and the article is forthwith distributed under the terms of the Pharmacokinetics of Gammaplex® 10% Versus Gammaplex® Creative Commons Attribution 4.0 International License (http:// 5% in Subjects with Primary Immunodeficiency, written by creativecommons.org/licenses/by/4.0/), which permits use, Richard L. Wasserman, Isaac R. Melamed, Mark R. Stein, duplication, adaptation, distribution and reproduction in any Stephen Jolles, Miranda Norton, James N. Moy and for the medium or format, as long as you give appropriate credit to http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Clinical Immunology Springer Journals

Erratum to: Evaluation of the Safety, Tolerability, and Pharmacokinetics of Gammaplex® 10% Versus Gammaplex® 5% in Subjects with Primary Immunodeficiency

Erratum to: Evaluation of the Safety, Tolerability, and Pharmacokinetics of Gammaplex® 10% Versus Gammaplex® 5% in Subjects with Primary Immunodeficiency

Abstract

J Clin Immunol (2017) 37:613 DOI 10.1007/s10875-017-0418-2 ERRATUM Erratum to: Evaluation of the Safety, Tolerability, and Pharmacokinetics of Gammaplex® 10% Versus Gammaplex® 5% in Subjects with Primary Immunodeficiency 1 2 3 4 Richard L. Wasserman & Isaac R. Melamed & Mark R. Stein & Stephen Jolles & 5 6 Miranda Norton & James N. Moy & for the GMX07 Study Group Published online: 17 July 2017 The Author(s) 2017. This article is an open access publication...
Loading next page...
 
/lp/springer_journal/erratum-to-evaluation-of-the-safety-tolerability-and-pharmacokinetics-a5LU80XHYy

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Springer Journals
Copyright
Copyright © 2017 by The Author(s)
Subject
Biomedicine; Immunology; Infectious Diseases; Internal Medicine; Medical Microbiology
ISSN
0271-9142
eISSN
1573-2592
DOI
10.1007/s10875-017-0418-2
Publisher site
See Article on Publisher Site

Abstract

J Clin Immunol (2017) 37:613 DOI 10.1007/s10875-017-0418-2 ERRATUM Erratum to: Evaluation of the Safety, Tolerability, and Pharmacokinetics of Gammaplex® 10% Versus Gammaplex® 5% in Subjects with Primary Immunodeficiency 1 2 3 4 Richard L. Wasserman & Isaac R. Melamed & Mark R. Stein & Stephen Jolles & 5 6 Miranda Norton & James N. Moy & for the GMX07 Study Group Published online: 17 July 2017 The Author(s) 2017. This article is an open access publication Erratum to: J Clin Immunol (2017) 37:301–310. page 301–310 the author decided to opt for Open Choice and DOI 10.1007/s10875-017-0383-9 to make the article an open access publication. Therefore, the copyright of the article has been changed to © The Author(s) The article Evaluation of the Safety, Tolerability, and 2017 and the article is forthwith distributed under the terms of the Pharmacokinetics of Gammaplex® 10% Versus Gammaplex® Creative Commons Attribution 4.0 International License (http:// 5% in Subjects with Primary Immunodeficiency, written by creativecommons.org/licenses/by/4.0/), which permits use, Richard L. Wasserman, Isaac R. Melamed, Mark R. Stein, duplication, adaptation, distribution and reproduction in any Stephen Jolles, Miranda Norton, James N. Moy and for the medium or format, as long as you give appropriate credit to

Journal

Journal of Clinical ImmunologySpringer Journals

Published: Jul 17, 2017

There are no references for this article.